CCI4EU - How to optimize molecular diagnostics in practice?
CCI4EU - 10th online course
CCI4EU - How to optimize molecular diagnostics in practice?
CCI4EU - 10th online course

Chairs
:
Laura Mezquita, ES; Richard Rosenquist Brandell, SECourse aim:
Next-generation sequencing technologies have revolutionized the field of molecular diagnostics in cancer. This course will explore the impact of molecular diagnostics on cancer diagnosis, prognosis, and treatment prediction, as well as the implications of identifying germline pathogenic variants. We will also examine how clinical decision support tools can assist Molecular Tumor Boards and inform clinical decision-making. Additionally, emerging technologies in precision cancer medicine will be discussed, along with best practice examples from precision cancer medicine programs.
Target audience:
Physicians/clinicians, researchers, management, coordinators, patients and patient advocates
Call for Cases:
Objective - To promote active and multidisciplinary learning through the analysis and discussion of clinical scenarios that reflect current challenges in the clinical application of biomarkers, targeted therapies, personalized medicine, and molecular data interpretation.
*The selected cases has been presented to the Experts during the live course on 4 November 2025
*Each case was allotted 10 minutes of time (including presentation and salient questions for the Experts).
Submission Requirements
- Language: English
- Format: Use the official template provided (attached - on righthand side of screen).
- Recommended length: 1–2 pages per section
- Required case content: Title, Authors and affiliation, Five Keywords, Introduction (clinical context/relevance), Case Presentation, Discussion (key elements of precision medicine), Conclusion, Optional Figure
Topics:
Section 1 (Molecular diagnosis in patients with hematological and solid tumours)
Section 2 (Impact of germline variants in cancer diagnostics)
Submission and Deadline:
- Deadline for submission: CALL EXTENDED until Friday, 10 October 2025
- Please note that you must be available to participate in the live course on 4 November 2025.
- Format: Template (attached - on righthand side of screen)
- Submission email: sgoldman@eso.net
- Subject line: “CCIEU 2025 Clinical Case – [First Author’s Name]”
Evaluation and Selection:
- Cases have been reviewed by the course’s scientific and teaching committee.
- Evaluation criteria included clinical quality, clarity, educational relevance, and the incorporation of precision medicine concepts.
- Selected cases have been chosen for interactive discussion during the course.
Live Streaming
Welcome
Molecular diagnosis in patients with hematological and solid tumours
Moving from cytogenetics to WGS in diagnostics of hematological malignancies
Lucia Cavelier (SE)Comprehensive genomic profiling in clinical routine; does it make sense for all patients?
Etienne Rouleau (FR)Treatment-agnostic tumors - how to organize the molecular diagnosis
Cristina Teixido (ES)Interactive Clinical Case Session - Case Presentation
Cesar Abel Centurion Rodriguez (PE)Live Panel Session
Lucia Cavelier (SE) Laura Mezquita (ES) Richard Rosenquist Brandell (SE) Etienne Rouleau (FR) Cristina Teixido (ES)Impact of germline variants in cancer diagnostics
Shifting from single gene test to comprehensive genomic profiling: implications on germline variant detection
Teresa Ramon y Cajal (ES)Clinical implications of germline findings ontreatment selection and cancer prevention
Elena Castro (ES)How to manage incidental pathogenic germline variants in somatic testing
Bianca Tesi (SE)Interactive Clinical Case Session - Case Presentation
Ahmed Mohsen Aboelfotoh Elalfy (EG)Live Panel Discussion
Laura Mezquita (ES) Teresa Ramon y Cajal (ES) Richard Rosenquist Brandell (SE) Bianca Tesi (SE)Break
New tools optimising diagnosis and management
Advances in Liquid Biopsy for Early Diagnosis and Disease Monitoring
Javier Hernández Losa (ES)Clinical Decisions for Optimizing Molecular Diagnosis for Patients with Solid Tumours
David Tamborero (SE)Proteogenomics and other -omics technologies
Janne Lehtiö (SE)Live Panel Discussion
Javier Hernández Losa (ES) Janne Lehtiö (SE) Laura Mezquita (ES) Richard Rosenquist Brandell (SE) David Tamborero (SE)Precision Medicine Programs in Cancer Centers
Precision medicine program in a comprehensive cancer center: experience & organization (first example)
Christophe Massard (FR)Precision medicine program in a comprehensive cancer center: experience & organization (second example)
Albrecht Stenzinger (DE)How is the organization of a Molecular Tumor Board in clinical practice
Hege G. Russnes (NO)Live Panel Discussion
Christophe Massard (FR) Laura Mezquita (ES) Richard Rosenquist Brandell (SE) Hege G. Russnes (NO) Albrecht Stenzinger (DE)Take Home Messages
Ahmed Mohsen Aboelfotoh Elalfy
Oncology Center Mansoura University, Medical Oncology Dpt., Mansoura, EG
Albrecht Stenzinger
Heidelberg University Hospital, Institute of Pathology, Heidelberg, DE
Bianca Tesi
, , ,
Cesar Abel Centurion Rodriguez
Instituto Nacional Enfermedades Neoplásicas Del Peru (inen), Medicina Oncologica, Lima, PE
Christophe Massard
Gustave Roussy Institute, Department of Therapeutic Innovation and Early Stage Trials, Villejuif, FR
Cristina Teixido
Hospital Clinic Barcelona, Somatic Molecular Diagnostics Biomedical Diagnostic Center, Barcelona, ES
David Tamborero
Karolinska Institutet, SciLifeLab, Stockholm, SE
Elena Castro
Hospital Universitario 12 de Octubre, Oncology Dept., Madrid, ES
Etienne Rouleau
Institut Gustave Roussy, Genetic Dept., Villejuif, FR
Hege G. Russnes
Oslo University Hospital, Department of Pathology, Oslo, NO
Janne Lehtiö
Karolinska Institutet, Department of Oncology and Pathology, Stockholm, SE
Javier Hernández Losa
Hospital Universitario Vall d´Hebron, Dept of Pathology, Barcelona, ES
Laura Mezquita
University of Barcelona, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, ES
Lucia Cavelier
Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, SE
Richard Rosenquist Brandell
Karolinksa Institutet, Clinical Genetics and Genomics, Solna,
Teresa Ramon y Cajal
Hospital Clinic of Barcelona, Medical Oncology, Barcelona, ES
